Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.06
NYSE:MNK's Cash-to-Debt is ranked lower than
96% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NYSE:MNK: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:MNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.08 Max: 0.31
Current: 0.06
0.04
0.31
Equity-to-Asset 0.35
NYSE:MNK's Equity-to-Asset is ranked lower than
85% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:MNK: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:MNK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.35 Max: 0.41
Current: 0.35
0.25
0.41
Debt-to-Equity 1.15
NYSE:MNK's Debt-to-Equity is ranked lower than
87% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NYSE:MNK: 1.15 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:MNK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.7  Med: 1.15 Max: 1.67
Current: 1.15
0.7
1.67
Interest Coverage 0.18
NYSE:MNK's Interest Coverage is ranked lower than
97% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. NYSE:MNK: 0.18 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MNK' s Interest Coverage Range Over the Past 10 Years
Min: 0.18  Med: 2.69 Max: 470.4
Current: 0.18
0.18
470.4
Piotroski F-Score: 5
Altman Z-Score: 0.53
Beneish M-Score: -2.61
WACC vs ROIC
12.13%
-2.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 2.17
NYSE:MNK's Operating Margin % is ranked lower than
60% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. NYSE:MNK: 2.17 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:MNK' s Operating Margin % Range Over the Past 10 Years
Min: 2.17  Med: 11.68 Max: 18.26
Current: 2.17
2.17
18.26
Net Margin % 13.93
NYSE:MNK's Net Margin % is ranked higher than
82% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. NYSE:MNK: 13.93 )
Ranked among companies with meaningful Net Margin % only.
NYSE:MNK' s Net Margin % Range Over the Past 10 Years
Min: -19.35  Med: 7 Max: 19.04
Current: 13.93
-19.35
19.04
ROE % 8.25
NYSE:MNK's ROE % is ranked higher than
64% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NYSE:MNK: 8.25 )
Ranked among companies with meaningful ROE % only.
NYSE:MNK' s ROE % Range Over the Past 10 Years
Min: -10.28  Med: 7.85 Max: 12.17
Current: 8.25
-10.28
12.17
ROA % 2.79
NYSE:MNK's ROA % is ranked higher than
50% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NYSE:MNK: 2.79 )
Ranked among companies with meaningful ROA % only.
NYSE:MNK' s ROA % Range Over the Past 10 Years
Min: -3.91  Med: 2.77 Max: 4.04
Current: 2.79
-3.91
4.04
ROC (Joel Greenblatt) % 5.95
NYSE:MNK's ROC (Joel Greenblatt) % is ranked lower than
51% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. NYSE:MNK: 5.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:MNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.34  Med: 18.27 Max: 50.3
Current: 5.95
3.34
50.3
3-Year Revenue Growth Rate 0.80
NYSE:MNK's 3-Year Revenue Growth Rate is ranked lower than
66% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NYSE:MNK: 0.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:MNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -11.2  Med: -10.1 Max: 0.8
Current: 0.8
-11.2
0.8
3-Year EBITDA Growth Rate 51.90
NYSE:MNK's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NYSE:MNK: 51.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:MNK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.5  Med: 11.5 Max: 51.9
Current: 51.9
-7.5
51.9
3-Year EPS without NRI Growth Rate 215.30
NYSE:MNK's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. NYSE:MNK: 215.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:MNK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -6.5  Med: 104.4 Max: 215.3
Current: 215.3
-6.5
215.3
GuruFocus has detected 1 Warning Sign with Mallinckrodt PLC $NYSE:MNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:MNK's 30-Y Financials

Financials (Next Earnings Date: 2017-11-29 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MNK Guru Trades in Q3 2016

Jim Simons 207,102 sh (New)
Paul Tudor Jones 7,336 sh (+35.00%)
Joel Greenblatt 327,572 sh (+32.71%)
First Eagle Investment 187 sh (unchged)
David Dreman 4,448 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 14,462 sh (-0.69%)
John Paulson 7,974,472 sh (-4.74%)
Ken Heebner 880,500 sh (-13.17%)
» More
Q4 2016

MNK Guru Trades in Q4 2016

Steven Cohen 120,900 sh (New)
Paul Tudor Jones 19,556 sh (+166.58%)
Mario Gabelli 17,425 sh (+20.49%)
John Paulson 7,976,872 sh (+0.03%)
First Eagle Investment 187 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Ken Heebner Sold Out
David Dreman 84 sh (-98.11%)
» More
Q1 2017

MNK Guru Trades in Q1 2017

HOTCHKIS & WILEY 818,140 sh (New)
Mario Gabelli 29,425 sh (+68.87%)
First Eagle Investment 187 sh (unchged)
David Dreman Sold Out
John Paulson 7,500,972 sh (-5.97%)
Steven Cohen 98,100 sh (-18.86%)
Paul Tudor Jones 9,234 sh (-52.78%)
» More
Q2 2017

MNK Guru Trades in Q2 2017

David Dreman 84 sh (New)
Steven Cohen 874,808 sh (+791.75%)
First Eagle Investment 187 sh (unchged)
Mario Gabelli 29,425 sh (unchged)
Paul Tudor Jones Sold Out
HOTCHKIS & WILEY 800,040 sh (-2.21%)
John Paulson 6,891,372 sh (-8.13%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Reduce -8.13%0.36%$39.63 - $46.92 $ 34.83-21%6,891,372
HOTCHKIS & WILEY 2017-06-30 Reduce -2.21%$39.63 - $46.92 $ 34.83-21%800,040
David Dreman 2017-06-30 New Buy$39.63 - $46.92 $ 34.83-21%84
John Paulson 2017-03-31 Reduce -5.97%0.3%$42.54 - $54.74 $ 34.83-29%7,500,972
HOTCHKIS & WILEY 2017-03-31 New Buy0.14%$42.54 - $54.74 $ 34.83-29%818,140
Mario Gabelli 2017-03-31 Add 68.87%$42.54 - $54.74 $ 34.83-29%29,425
David Dreman 2017-03-31 Sold Out $42.54 - $54.74 $ 34.83-29%0
John Paulson 2016-12-31 Add 0.03%$49.51 - $71.17 $ 34.83-41%7,976,872
Mario Gabelli 2016-12-31 Add 20.49%$49.51 - $71.17 $ 34.83-41%17,425
David Dreman 2016-12-31 Reduce -98.11%0.19%$49.51 - $71.17 $ 34.83-41%84
Joel Greenblatt 2016-12-31 Sold Out 0.3%$49.51 - $71.17 $ 34.83-41%0
Ken Heebner 2016-12-31 Sold Out 2.9%$49.51 - $71.17 $ 34.83-41%0
John Paulson 2016-09-30 Reduce -4.74%0.25%$60.22 - $83.06 $ 34.83-52%7,974,472
Ken Heebner 2016-09-30 Reduce -13.17%0.36%$60.22 - $83.06 $ 34.83-52%880,500
Joel Greenblatt 2016-09-30 Add 32.71%0.07%$60.22 - $83.06 $ 34.83-52%327,572
Mario Gabelli 2016-09-30 Reduce -0.69%$60.22 - $83.06 $ 34.83-52%14,462
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:LSE:HIK, LSE:APH, LSE:BMK, LSE:STX, LSE:SPH, LSE:QP., LSE:SUMM, LSE:DNL, LSE:AMYT, LSE:SIS, LSE:VLG, LSE:EVG, NAS:MYL » details
Traded in other countries:MCD.Germany,
Headquarter Location:UK
Mallinckrodt PLC is a drug manufacturing company that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products. It operates in two segments including branded pharmaceuticals and generic drugs.

Mallinckrodt is a specialty pharmaceutical company that was spun off from Covidien. The company has two segments in branded pharmaceuticals and generic drugs following the sale of its nuclear imaging business in 2016. Branded drugs make up approximately 70% of revenue. The firm's generic drug segment focuses primarily on products in the pain therapeutic area.

Ratios

vs
industry
vs
history
PE Ratio 8.46
MNK's PE Ratio is ranked higher than
93% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.93 vs. MNK: 8.46 )
Ranked among companies with meaningful PE Ratio only.
MNK' s PE Ratio Range Over the Past 10 Years
Min: 7.76  Med: 20.05 Max: 73.31
Current: 8.46
7.76
73.31
Forward PE Ratio 4.25
MNK's Forward PE Ratio is ranked higher than
96% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. MNK: 4.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 6.48
MNK's Price-to-Owner-Earnings is ranked higher than
92% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. MNK: 6.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.26  Med: 7.85 Max: 10.23
Current: 6.48
6.26
10.23
PB Ratio 0.64
MNK's PB Ratio is ranked higher than
91% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. MNK: 0.64 )
Ranked among companies with meaningful PB Ratio only.
MNK' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.98 Max: 3.59
Current: 0.64
0.64
3.59
PS Ratio 1.19
MNK's PS Ratio is ranked higher than
73% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MNK: 1.19 )
Ranked among companies with meaningful PS Ratio only.
MNK' s PS Ratio Range Over the Past 10 Years
Min: 1.11  Med: 2.35 Max: 6.35
Current: 1.19
1.11
6.35
Price-to-Free-Cash-Flow 9.09
MNK's Price-to-Free-Cash-Flow is ranked higher than
88% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. MNK: 9.09 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MNK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.55  Med: 11.38 Max: 2749.62
Current: 9.09
5.55
2749.62
Price-to-Operating-Cash-Flow 5.89
MNK's Price-to-Operating-Cash-Flow is ranked higher than
87% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. MNK: 5.89 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MNK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.7  Med: 12.85 Max: 45.78
Current: 5.89
4.7
45.78
EV-to-EBIT 128.05
MNK's EV-to-EBIT is ranked lower than
89% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. MNK: 128.05 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s EV-to-EBIT Range Over the Past 10 Years
Min: 19.4  Med: 49.65 Max: 231
Current: 128.05
19.4
231
EV-to-EBITDA 10.05
MNK's EV-to-EBITDA is ranked higher than
77% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. MNK: 10.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.1  Med: 13.45 Max: 34.2
Current: 10.05
8.1
34.2
EV-to-Revenue 2.94
MNK's EV-to-Revenue is ranked higher than
51% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. MNK: 2.94 )
Ranked among companies with meaningful EV-to-Revenue only.
MNK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 3.8 Max: 8.9
Current: 2.94
1.5
8.9
Current Ratio 1.06
MNK's Current Ratio is ranked lower than
75% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MNK: 1.06 )
Ranked among companies with meaningful Current Ratio only.
MNK' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 2.03 Max: 2.86
Current: 1.06
1.06
2.86
Quick Ratio 0.81
MNK's Quick Ratio is ranked lower than
74% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. MNK: 0.81 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.53 Max: 2.41
Current: 0.81
0.81
2.41
Days Inventory 89.58
MNK's Days Inventory is ranked higher than
65% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. MNK: 89.58 )
Ranked among companies with meaningful Days Inventory only.
MNK' s Days Inventory Range Over the Past 10 Years
Min: 71.49  Med: 81.23 Max: 169.11
Current: 89.58
71.49
169.11
Days Sales Outstanding 57.83
MNK's Days Sales Outstanding is ranked higher than
68% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. MNK: 57.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.29  Med: 73.29 Max: 105.41
Current: 57.83
50.29
105.41
Days Payable 29.28
MNK's Days Payable is ranked lower than
87% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. MNK: 29.28 )
Ranked among companies with meaningful Days Payable only.
MNK' s Days Payable Range Over the Past 10 Years
Min: 26.34  Med: 41.19 Max: 52.77
Current: 29.28
26.34
52.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.90
MNK's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. MNK: -22.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.3  Med: -26.2 Max: -22.9
Current: -22.9
-26.3
-22.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.50
MNK's Price-to-Median-PS-Value is ranked higher than
87% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. MNK: 0.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 0.98 Max: 2.51
Current: 0.5
0.49
2.51
Earnings Yield (Greenblatt) % 0.79
MNK's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MNK: 0.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 2 Max: 5.1
Current: 0.79
0.4
5.1

More Statistics

Revenue (TTM) (Mil) $3,042.70
EPS (TTM) $ 4.11
Beta1.51
Short Percentage of Float18.68%
52-Week Range $33.61 - 76.81
Shares Outstanding (Mil)97.18

Analyst Estimate

Sep17 Sep18 Sep19 Sep20
Revenue (Mil $) 3,289 3,322 3,337 3,364
EPS ($) 7.40 8.18 8.91 9.75
EPS without NRI ($) 7.40 8.18 8.91 9.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.81%
Dividends per Share ($)
» More Articles for MNK

Headlines

Articles On GuruFocus.com
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse i Sep 22 2017 
Mallinckrodt Announces Election Of David Norton To Its Board Of Directors Sep 20 2017 
Stull, Stull & Brody Reminds Investors of Class Action Lawsuit on Behalf of Employee Benefit Plan Pu Sep 01 2017 
Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare Conference Aug 15 2017 
Mallinckrodt To Present At Wells Fargo Securities 2017 Healthcare Conference Aug 07 2017 
Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Thera Aug 04 2017 
Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation Aug 01 2017 
Summary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injectio Jul 31 2017 
U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced Therapy Jul 18 2017 
Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of Schedule Jul 13 2017 

More From Other Websites
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse... Sep 22 2017
See what the IHS Markit Score report has to say about Mallinckrodt Plc. Sep 21 2017
Mallinckrodt Announces Election Of David Norton To Its Board Of Directors Sep 20 2017
ETFs with exposure to Mallinckrodt Plc : September 14, 2017 Sep 14 2017
Mallinckrodt Plc :MNK-US: Earnings Analysis: Q3, 2017 By the Numbers : September 13, 2017 Sep 13 2017
Early movers: DIS, JWN, AAL, AGN, CNC, TEX, MU, MNK & more Sep 13 2017
The most respected medical journal in the US just eviscerated a drug that's cost taxpayers over $1... Sep 12 2017
A furious employee is suing drugmaker Mallinckrodt over claims about its $38,000-a-dose blockbuster Sep 07 2017
Mallinckrodt Down as District Court Invalidates Inomax Patents Sep 06 2017
Why Mallinckrodt Got Crushed Sep 05 2017
Why Mallinckrodt, Universal Insurance Holdings, and Cellectis Slumped Today Sep 05 2017
What's Behind Mallinckrodt's 12.2% Tumble Today Sep 05 2017
Wall Street's most hated pharma company just lost a lifeline Sep 05 2017
Mallinckrodt is getting crushed after a judge invalidated many of its patents Sep 05 2017
The Stock Market Gets Smashed -- Here Are Some Terrible Performers Sep 05 2017
U.S. judge invalidates Mallinckrodt patents on respiratory treatment Sep 05 2017
Stull, Stull & Brody Reminds Investors of Class Action Lawsuit on Behalf of Employee Benefit Plan... Sep 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}